MannKind to Participate in 2022 Medicare Part D Senior Savin

[cedafuntennis]

Mar 15, 2021 21:26:45 GMT -5 nylefty said:

Mar 15, 2021 21:08:40 GMT -5 ryster505 said:

So, out of curiosity just how big is this news? Was this somewhat expected? Is this a total surprise? Just curious as the stock has yet to react.

I don't think it's a big deal at all. MannKind could have joined Big Pharma in this program this year or slashed prices on its own, but it didn't have the money to do that.

It may mean getting a lot more people on Afrezza next year, but at the cost of losing money on every prescription. That may be worth it in terms of getting the word out, but I see no reason for it to affect the stock price anytime this year. 

except that bigger volumes mean drastically lower production costs, more data and more exposure for the drug and maybe measure importantly for the technology behind it.

[hindsight2]

Medicare part d is a stand alone plan or Medicare advantage plan that includes part d benefits. Either way it's an out of pocket prescription insurance plan.

[uvula]

Also, if we ignore the investment angle for a minute, this has the potential to make a lot of people healthier. This is really what matters. And we as investors get some credit for enabling this!

[nylefty]

Mar 15, 2021 21:08:40 GMT -5 ryster505 said:

So the patient pays $35 at the pharmacy and all the middlemen take their cuts. How much is left for MannKind? What's your guess?

[longliner]

Mar 16, 2021 21:33:19 GMT -5 nylefty said:

Mar 15, 2021 21:08:40 GMT -5 ryster505 said:

So, out of curiosity just how big is this news? Was this somewhat expected? Is this a total surprise? Just curious as the stock has yet to react.

So the patient pays $35 at the pharmacy and all the middlemen take their cuts. How much is left for MannKind? What's your guess?

I don't know the breakdown, however I would think a major BP looking to partner for Afrezza would see this an advantage.  Volume would matter for BP.  I don't know how the recent funding may change things, Mike has said in the recent past that he anticipated a partner for pediatric trials.